Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
Part 2: Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Healthcare coverage is heterogeneous across emerging markets, with public funding limited by budgetary constraints. This typically sees higher-priced drugs,...